The European Organization for Research and Treatment of Cancer (EORTC) was established in 1962 to develop, conduct, coordinate and stimulate research on the experimental and clinical bases of cancer treatment in Europe. In 1974, the data management and statistical center (EORTC Data Center) of the organization was created with support from the NCI. The EORTC Data Center provides logistic and scientific support (data management, statistics and medical) to 21 EORTC Clinical Research Groups with respect to the management of clinical trials and related research projects. The Data Center has also developed a large expertise in regulatory affairs and safety dealing with more than 35 countries with different laws and regulations. The Data Center is also a research center involved in: the development of telematics applications to support tissue research (Virtual Tumor Bank), the methodological aspects of clinical trials at various levels (surrogate endpoints, meta-analysis, quality of life, RECIST, treatment outcome), and the development of European and national policies dealing with human research. The EORTC Data Center greatly facilitates collaboration between cooperative research groups providing support in the organization and conduct of large intergroup trials.
The aim of this competing continuation grant application is to request continuation of the support that the EORTC Data Center has received without interruption since 1974 so that it can pursue, reinforce and expand the range of services which it offers to the well established network of investigators participating in the activities of the EORTC Clinical Research Groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA011488-36
Application #
6957494
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1981-12-01
Project End
2010-11-30
Budget Start
2006-05-04
Budget End
2006-11-30
Support Year
36
Fiscal Year
2006
Total Cost
$417,479
Indirect Cost
Name
European Org/Research/Treatment/Cancer
Department
Type
DUNS #
763839466
City
Brussels
State
Country
Belgium
Zip Code
1200
Tajik, Parvin; van de Vrie, Roelien; Zafarmand, Mohammad H et al. (2018) The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy. Int J Gynecol Cancer 28:453-458
Ediebah, Divine E; Reijneveld, Jaap C; Taphoorn, Martin J B et al. (2017) Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res 26:869-880
Seymour, Lesley; Bogaerts, Jan; Perrone, Andrea et al. (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143-e152
Schwartz, Lawrence H; Litière, Saskia; de Vries, Elisabeth et al. (2016) RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 62:132-7
Baumert, Brigitta G; Hegi, Monika E; van den Bent, Martin J et al. (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521-1532
Schwartz, Lawrence H; Seymour, Lesley; Litière, Saskia et al. (2016) RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 62:138-45
Bonnefoi, H; Jacot, W; Saghatchian, M et al. (2015) Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 26:325-32
Ediebah, Divine E; Galindo-Garre, Francisca; Uitdehaag, Bernard M J et al. (2015) Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res 24:795-804
Fei, F; Messina, C; Slaets, L et al. (2015) Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. Eur J Cancer 51:301-9
Oosterveld, Margriet; Suciu, Stefan; Muus, Petra et al. (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie Ann Hematol 94:23-34

Showing the most recent 10 out of 338 publications